Cancer arises from somatic mutations accumulating within a cell, disrupting critical regulatory pathways governing cell growth, differentiation, and apoptosis.  Advances in genomic sequencing technologies have revolutionized our understanding of the genetic basis of cancer, revealing the heterogeneous nature of tumors and identifying specific driver mutations underpinning their development and progression. This wealth of data has fueled the emergence of personalized medicine, enabling tailored therapeutic strategies based on an individual patient's unique tumor genotype.  Targeted therapies, such as tyrosine kinase inhibitors and immune checkpoint inhibitors, selectively target specific oncogenic mutations or immune evasion mechanisms, offering improved efficacy and reduced toxicity compared to conventional chemotherapies.  Furthermore,  circulating tumor DNA (ctDNA) analysis allows for non-invasive monitoring of residual disease and early detection of relapse, enabling proactive adjustments to treatment regimens.  While challenges remain, including the identification of optimal biomarkers and the cost-effectiveness of extensive genomic profiling, the integration of genomic data into clinical decision-making represents a significant step towards a more precise and effective approach to cancer treatment, ultimately improving patient outcomes and quality of life.  Ongoing research focused on identifying novel therapeutic targets and developing more sophisticated predictive models will further enhance the impact of personalized medicine in oncology.